LGND vs. HALO, MDGL, ALKS, IONS, FOLD, DVAX, BCRX, MNKD, GERN, and CLDX
Should you be buying Ligand Pharmaceuticals stock or one of its competitors? The main competitors of Ligand Pharmaceuticals include Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), Ionis Pharmaceuticals (IONS), Amicus Therapeutics (FOLD), Dynavax Technologies (DVAX), BioCryst Pharmaceuticals (BCRX), MannKind (MNKD), Geron (GERN), and Celldex Therapeutics (CLDX). These companies are all part of the "biotechnology" industry.
Ligand Pharmaceuticals vs.
Ligand Pharmaceuticals (NASDAQ:LGND) and Halozyme Therapeutics (NASDAQ:HALO) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, community ranking, institutional ownership and earnings.
Halozyme Therapeutics has a net margin of 43.74% compared to Ligand Pharmaceuticals' net margin of 29.68%. Halozyme Therapeutics' return on equity of 157.78% beat Ligand Pharmaceuticals' return on equity.
Ligand Pharmaceuticals has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500.
Halozyme Therapeutics has higher revenue and earnings than Ligand Pharmaceuticals. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.
Ligand Pharmaceuticals received 25 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. Likewise, 70.77% of users gave Ligand Pharmaceuticals an outperform vote while only 69.53% of users gave Halozyme Therapeutics an outperform vote.
Ligand Pharmaceuticals presently has a consensus price target of $147.00, indicating a potential upside of 31.04%. Halozyme Therapeutics has a consensus price target of $62.78, indicating a potential upside of 8.31%. Given Ligand Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Ligand Pharmaceuticals is more favorable than Halozyme Therapeutics.
91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 5.9% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 2.4% of Halozyme Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Ligand Pharmaceuticals had 3 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 22 mentions for Ligand Pharmaceuticals and 19 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.93 beat Ligand Pharmaceuticals' score of 0.51 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.
Summary
Halozyme Therapeutics beats Ligand Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Ligand Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ligand Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:LGND) was last updated on 3/4/2025 by MarketBeat.com Staff
